Andre Goy, MD, MS

Articles

Dr. Goy Discusses Challenges in Treatment of MCL

March 6th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses challenges in the treatment of patients with mantle cell lymphoma.

Dr. Goy Discusses the Cost of CAR T-Cell Therapy

January 12th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Goy Discusses the Rituximab Biosimilar FDA Approval

November 29th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the FDA approval of the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

Dr. Goy on Need for Payment Model for CAR T-Cell Therapy

November 17th 2018

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.

Dr. Goy on Lenalidomide as Management for Patients With MCL

April 17th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goy on Bendamustine Plus Cytarabine as MCL Treatment

March 21st 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of bendamustine plus cytarabine as treatment for patients with mantle cell lymphoma.

Dr. Goy on Advancements in Relapsed/Refractory Mantle Cell Lymphoma

March 6th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent therapeutic advancements in the field of mantle cell lymphoma (MCL).

Dr. Goy on Efficacy With Ibrutinib in MCL

February 22nd 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

Dr. Goy on Impact of Lenalidomide on MCL Treatment

February 9th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the impact lenalidomide (Revlimid) has had on the treatment paradigm of mantle cell lymphoma (MCL).

Dr. Goy on Takeaways in Mantle Cell Lymphoma for the Future

February 4th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).

Dr. Goy on the Role of Immunotherapy in Mantle Cell Lymphoma

February 1st 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses immunotherapy agents currently being evaluated in the treatment of patients with mantle cell lymphoma.

Dr. Goy on Approved Agents in the Treatment Landcsape of MCL

January 26th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses novel agents approved for the treatment of patients with mantle cell lymphoma.

Dr. Goy on the Role of MRD in Mantle Cell Lymphoma

January 18th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of minimal residual disease in the treatment of patients with mantle cell lymphoma.

Dr. Goy on Combination Therapies in Mantle Cell Lymphoma

January 12th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Dr. Goy on Bortezomib in MCL Treatment

December 30th 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Dr. Goy on Rituximab Maintenance Therapy for Patients With MCL

December 21st 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.

Dr. Goy on Changing Treatment Landscape of Mantle Cell Lymphoma

December 20th 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma is evolving.

Unprecedented Changes in Oncology: Toward a New Dawn

February 17th 2014

"Are you making progress?" is one of the questions you are most frequently being asked as an oncologist-even in social settings.

Can We Hope for the Best From the Affordable Care Act?

January 23rd 2014

The classic saying Have a Happy and Healthy New Year takes a particularly important meaning this year, as Jan 1, 2014, is now a landmark date in the history of US healthcare with the implementation of the Affordable Care Act (ACA), also referred to as Obamacare

Novel Agents in Practice: Outcomes at What Cost?

January 5th 2013

The real question is how will we best use our continually evolving armamentarium of treatments to deliver the best outcomes while optimizing the cost of care for our patients.